Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
-
- Mizuno Tomoko
- Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan
-
- Inoshita Naoko
- Department of Pathology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology Hospital, Japan Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan
-
- Fukuhara Noriaki
- Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan
-
- Tatsushima Keita
- Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan
-
- Takeshita Akira
- Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan
-
- Yamada Shozo
- Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan Neurosurgery Center, Moriyama Memorial Hospital, Japan
-
- Nishioka Hiroshi
- Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Japan
-
- Takeuchi Yasuhiro
- Department of Endocrinolgy and Metabolism, Toranomon Hospital, Japan
この論文をさがす
抄録
<p>Pasireotide, which has a high affinity for somatostatin receptor (SSTR) 5, has attracted attention as a new treatment for refractory Cushing's disease. The patient was a 28-year-old man. He had refractory Cushing's disease and underwent multiple surgeries, radiotherapy, and medication therapy. An examination of the adenoma by immunohistochemistry revealed a low SSTR5 expression. An USP8 mutation was not detected by reverse transcription polymerase chain reaction. Although we administered pasireotide, it was ineffective. While a further investigation is necessary, the analysis of SSTR5 expression may support the prediction of the efficiency of pasireotide for Cushing's disease. We report this case as a useful reference when considering whether or not to use pasireotide for refractory corticotroph adenomas. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 61 (5), 679-685, 2022-03-01
一般社団法人 日本内科学会